These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
310 related articles for article (PubMed ID: 3041218)
1. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. Rodenhuis S; van de Wetering ML; Mooi WJ; Evers SG; van Zandwijk N; Bos JL N Engl J Med; 1987 Oct; 317(15):929-35. PubMed ID: 3041218 [TBL] [Abstract][Full Text] [Related]
2. Mutations of K-ras oncogene and absence of H-ras mutations in squamous cell carcinomas of the lung. Vachtenheim J; Horáková I; Novotná H; Opáalka P; Roubková H Clin Cancer Res; 1995 Mar; 1(3):359-65. PubMed ID: 9815992 [TBL] [Abstract][Full Text] [Related]
3. Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung. Rodenhuis S; Slebos RJ; Boot AJ; Evers SG; Mooi WJ; Wagenaar SS; van Bodegom PC; Bos JL Cancer Res; 1988 Oct; 48(20):5738-41. PubMed ID: 3048648 [TBL] [Abstract][Full Text] [Related]
4. Role of epidermal growth factor receptor overexpression, K-ras point mutation and c-myc amplification in the carcinogenesis of non-small cell lung cancer. Sekine I; Takami S; Guang SG; Yokose T; Kodama T; Nishiwaki Y; Kinoshita M; Matsumoto H; Ogura T; Nagai K Oncol Rep; 1998; 5(2):351-4. PubMed ID: 9468555 [TBL] [Abstract][Full Text] [Related]
5. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. Slebos RJ; Kibbelaar RE; Dalesio O; Kooistra A; Stam J; Meijer CJ; Wagenaar SS; Vanderschueren RG; van Zandwijk N; Mooi WJ N Engl J Med; 1990 Aug; 323(9):561-5. PubMed ID: 2199829 [TBL] [Abstract][Full Text] [Related]
6. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Rosell R; Li S; Skacel Z; Mate JL; Maestre J; Canela M; Tolosa E; Armengol P; Barnadas A; Ariza A Oncogene; 1993 Sep; 8(9):2407-12. PubMed ID: 8395679 [TBL] [Abstract][Full Text] [Related]
7. K-ras activation in non-small cell lung cancer in the dog. Kraegel SA; Gumerlock PH; Dungworth DL; Oreffo VI; Madewell BR Cancer Res; 1992 Sep; 52(17):4724-7. PubMed ID: 1324792 [TBL] [Abstract][Full Text] [Related]
8. Activation of protooncogenes in spontaneously occurring non-liver tumors from C57BL/6 x C3H F1 mice. Candrian U; You M; Goodrow T; Maronpot RR; Reynolds SH; Anderson MW Cancer Res; 1991 Feb; 51(4):1148-53. PubMed ID: 1997158 [TBL] [Abstract][Full Text] [Related]
9. Activation of K-ras by codon 13 mutations in C57BL/6 X C3H F1 mouse tumors induced by exposure to 1,3-butadiene. Goodrow T; Reynolds S; Maronpot R; Anderson M Cancer Res; 1990 Aug; 50(15):4818-23. PubMed ID: 2196119 [TBL] [Abstract][Full Text] [Related]
10. Detection of activated K-ras in non-small cell lung cancer by membrane array: a comparison with direct sequencing. Chong IW; Chang MY; Sheu CC; Wang CY; Hwang JJ; Huang MS; Lin SR Oncol Rep; 2007 Jul; 18(1):17-24. PubMed ID: 17549340 [TBL] [Abstract][Full Text] [Related]
11. [Detection of K-ras oncogene activation in human lung cancer and its possible clinical application]. Zhang G; Sun Y; Wang M Zhonghua Jie He He Hu Xi Za Zhi; 1995 Oct; 18(5):282-4, 317. PubMed ID: 8762479 [TBL] [Abstract][Full Text] [Related]
12. Occurrence of ras mutations in human lung cancer. Minireview. Vachtenheim J Neoplasma; 1997; 44(3):145-9. PubMed ID: 9372854 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of ras oncogene activation in human lung cancer. Rodenhuis S; Slebos RJ Cancer Res; 1992 May; 52(9 Suppl):2665s-2669s. PubMed ID: 1562997 [TBL] [Abstract][Full Text] [Related]
14. Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Mills NE; Fishman CL; Rom WN; Dubin N; Jacobson DR Cancer Res; 1995 Apr; 55(7):1444-7. PubMed ID: 7882350 [TBL] [Abstract][Full Text] [Related]
15. The presence of K-12 ras mutations in duodenal adenocarcinomas and the absence of ras mutations in other small bowel adenocarcinomas and carcinoid tumors. Younes N; Fulton N; Tanaka R; Wayne J; Straus FH; Kaplan EL Cancer; 1997 May; 79(9):1804-8. PubMed ID: 9128999 [TBL] [Abstract][Full Text] [Related]
16. Ras oncogene point mutation: an infrequent event in bronchioloalveolar cancer. Rusch VW; Reuter VE; Kris MG; Kurie J; Miller WH; Nanus DM; Albino AP; Dmitrovsky E J Thorac Cardiovasc Surg; 1992 Nov; 104(5):1465-9. PubMed ID: 1331621 [TBL] [Abstract][Full Text] [Related]
17. ERBB2 kinase domain mutation in the lung squamous cell carcinoma. Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927 [TBL] [Abstract][Full Text] [Related]
18. Molecular staging of non-small cell lung cancer according to K-ras genotypes. Rosell R; Monzó M; Pifarré A; Ariza A; Sánchez JJ; Moreno I; Maurel J; López MP; Abad A; de Anta JM Clin Cancer Res; 1996 Jun; 2(6):1083-6. PubMed ID: 9816271 [TBL] [Abstract][Full Text] [Related]
19. ras mutations and expression in head and neck squamous cell carcinomas. Yarbrough WG; Shores C; Witsell DL; Weissler MC; Fidler ME; Gilmer TM Laryngoscope; 1994 Nov; 104(11 Pt 1):1337-47. PubMed ID: 7968162 [TBL] [Abstract][Full Text] [Related]
20. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Mitsudomi T; Viallet J; Mulshine JL; Linnoila RI; Minna JD; Gazdar AF Oncogene; 1991 Aug; 6(8):1353-62. PubMed ID: 1679529 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]